Literature DB >> 23890739

Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function.

Arsime Demjaha1, Alice Egerton2, Robin M Murray3, Shitij Kapur3, Oliver D Howes1, James M Stone4, Philip K McGuire3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23890739     DOI： 10.1016/j.biopsych.2013.06.011

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN： 0006-3223            Impact factor:   13.382


× No keyword cloud information.
  108 in total

Review 1.  Glutamate-mediated excitotoxicity in schizophrenia: a review.

Authors:  Eric Plitman; Shinichiro Nakajima; Camilo de la Fuente-Sandoval; Philip Gerretsen; M Mallar Chakravarty; Jane Kobylianskii; Jun Ku Chung; Fernando Caravaggio; Yusuke Iwata; Gary Remington; Ariel Graff-Guerrero
Journal:  Eur Neuropsychopharmacol       Date:  2014-08-01       Impact factor: 4.600

Review 2.  Neuroimaging markers of antipsychotic treatment response in schizophrenia: An overview of magnetic resonance imaging studies.

Authors:  Goda Tarcijonas; Deepak K Sarpal
Journal:  Neurobiol Dis       Date:  2018-06-25       Impact factor: 5.996

3.  Clozapine response trajectories and predictors of non-response in treatment-resistant schizophrenia: a chart review study.

Authors:  Parita Shah; Yusuke Iwata; Eric E Brown; Julia Kim; Marcos Sanches; Hiroyoshi Takeuchi; Shinichiro Nakajima; Margaret Hahn; Gary Remington; Philip Gerretsen; Ariel Graff-Guerrero
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2019-08-19       Impact factor: 5.270

4.  The contribution of neuroimaging to understanding schizophrenia; past, present, and future.

Authors:  Iris E Sommer; René S Kahn
Journal:  Schizophr Bull       Date:  2014-10-27       Impact factor: 9.306

5.  The mGluR2/3 agonist pomaglumetad methionil normalizes aberrant dopamine neuron activity via action in the ventral hippocampus.

Authors:  Susan F Sonnenschein; Anthony A Grace
Journal:  Neuropsychopharmacology       Date:  2020-07-14       Impact factor: 7.853

6.  Ultrastructural evidence for glutamatergic dysregulation in schizophrenia.

Authors:  Rosalinda C Roberts; Lesley A McCollum; Kirsten E Schoonover; Samuel J Mabry; Joy K Roche; Adrienne C Lahti
Journal:  Schizophr Res       Date:  2020-01-31       Impact factor: 4.939

7.  Hippocampus and cognitive domain deficits in treatment-resistant schizophrenia: A comparison with matched treatment-responsive patients and healthy controls✰,✰✰,★,★★.

Authors:  Junchao Huang; Yu Zhu; Fengmei Fan; Song Chen; Yuan Hong; Yimin Cui; Xingguang Luo; Shuping Tan; Zhiren Wang; Lan Shang; Ying Yuan; Jianxin Zhang; Fude Yang; Chiang-Shan R Li; Laura M Rowland; Peter Kochunov; Fengyu Zhang; L Elliot Hong; Yunlong Tan
Journal:  Psychiatry Res Neuroimaging       Date:  2020-02-04       Impact factor: 2.376

8.  Altered Glutamate and Regional Cerebral Blood Flow Levels in Schizophrenia: A 1H-MRS and pCASL study.

Authors:  S Andrea Wijtenburg; Susan N Wright; Stephanie A Korenic; Frank E Gaston; Nkemdilim Ndubuizu; Joshua Chiappelli; Robert P McMahon; Hongji Chen; Anya Savransky; Xiaoming Du; Danny J J Wang; Peter Kochunov; L Elliot Hong; Laura M Rowland
Journal:  Neuropsychopharmacology       Date:  2016-08-26       Impact factor: 7.853

9.  Pharmacogenetic associations of the type-3 metabotropic glutamate receptor (GRM3) gene with working memory and clinical symptom response to antipsychotics in first-episode schizophrenia.

Authors:  Jeffrey R Bishop; James L Reilly; Margret S H Harris; Shitalben R Patel; Rick Kittles; Judith A Badner; Konasale M Prasad; Vishwajit L Nimgaonkar; Matcheri S Keshavan; John A Sweeney
Journal:  Psychopharmacology (Berl)       Date:  2014-08-07       Impact factor: 4.530

10.  Accessing Gene Expression in Treatment-Resistant Schizophrenia.

Authors:  Patricia N Moretti; Vanessa K Ota; Eduardo S Gouvea; Mariana Pedrini; Marcos L Santoro; Fernanda Talarico; Leticia M Spindola; Carolina Muniz Carvalho; Cristiano Noto; Gabriela Xavier; Elisa Brietzke; Ary Gadelha; Rodrigo Bressan; Jair Mari; Sintia Belangero
Journal:  Mol Neurobiol       Date:  2018-01-26       Impact factor: 5.590
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.